Kromatid Incorporated

11/19/2021

https://conta.cc/2YZMOng

The latest advancements in single-cell analysis Transforming the world through the discovery of chromosomal rearrangements and the confirmation of CRISPR or other edits in engineered cells. About Krom

11/15/2021

https://conta.cc/3qvGG1B

11/11/2021

KromaTiD Announces Launch of dGH SCREEN™ for Unbiased Whole Genome Analysis of Chromosomal Structural Rearrangements

Longmont, CO September 2, 2021 – KromaTiD is pleased to announce the launch of dGH Screen™, their new service for mapping the human genome in single cells. dGH SCREEN™ is built upon KromaTiD’s proprietary directional Genomic Hybridization technology, a platform for measuring genomic structure and structural variation. Using dGH Screen, researchers worldwide can now visualize the structure of the human genome and discover structural variation in a completely de novo fashion at the unprecedented resolution of 5Kb.

KromaTiD has already partnered with researchers at NIST, UTMB, CSU and the University of Connecticut to use dGH Screen™ for preliminary studies analyzing genomic structural variation in a variety of contexts including rare disease, radiation exposure, and CRISPR Cas-9 genome editing.

“Researchers who rely only on next generation sequencing (NGS) only to discover or detect variation often miss important structural rearrangements to the genome.” Says Dr. Christopher Tompkins, KromaTiD’s Chief Technology Officer. “dGH Screen provides “the genomic ground truth”, a direct, definitive measurement of structural variation that does not employ bioinformatic methods to recalculate structure from pooled, digested DNA – methods that can often lead to false negative and false positive results for structural variation.”

Visit our website for more information:

dGH SCREEN™ is a single cell assay designed to monitor structural variants throughout the genome in an entirely de novo fashion. By utilizing directional Genomic Hybridization technology combined with fluorescence labeling patterns and chromosomal aggregation strategies, dGH SCREEN provides the mo...

11/11/2021

CRISPR-editing biotech Arbor Bio adds $215M for liver, CNS disease therapies.

Arbor Biotechnologies raised new cash to keep up the pace in the chase for new genetic medicines. The MIT spinout applies artificial intelligence and machine learning to discover CRISPR enzymes applicable for gene-editing therapies; the Series B financing comes as programs in liver and central nervo...

11/11/2021

dGH Screen efficient tool for detecting DNA damage, and understanding off target effects of CRISPR edits.

Dr. Christopher Tompkins, CTO and Erin Cross, Director of Whole Genome Research and Development at KromaTiD present the newest whole-genome, karyotyping assa...